Holen Sie sich die Stockscreener-App
167.16
1.10%
-1.375
Schlusskurs vom Vortag:
$168.53
Offen:
$168.53
24-Stunden-Volumen:
159.43K
Relative Volume:
0.15
Marktkapitalisierung:
$9.43B
Einnahmen:
$763.34M
Nettoeinkommen (Verlust:
$51.40M
KGV:
184.01
EPS:
0.9084
Netto-Cashflow:
$104.46M
1W Leistung:
-3.62%
1M Leistung:
+1.69%
6M Leistung:
+30.33%
1J Leistung:
+40.43%
1-Tages-Spanne:
$166.00
$169.52
1-Wochen-Bereich:
$165.00
$176.13
52-Wochen-Spanne:
$100.99
$188.73
Repligen Corp Stock (RGEN) Company Profile
Firmenname
Repligen Corp
Sektor
Telefon
(781) 449-9560
Adresse
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
167.15 | 9.51B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
350.73 | 123.70B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.99 | 48.78B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
68.91 | 33.41B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
219.90 | 31.89B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
34.77 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-01 | Eingeleitet | HSBC Securities | Buy |
| 2025-09-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-29 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | Evercore ISI | In-line |
| 2025-02-10 | Eingeleitet | TD Cowen | Buy |
| 2024-12-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-07-20 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-03-28 | Eingeleitet | The Benchmark Company | Buy |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2021-10-14 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-11-01 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-28 | Bestätigt | First Analysis Sec | Outperform |
| 2019-08-23 | Fortgesetzt | Stephens | Overweight |
| 2019-07-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | Hochstufung | CL King | Neutral → Buy |
| 2018-11-12 | Herabstufung | CL King | Buy → Neutral |
| 2018-09-26 | Eingeleitet | H.C. Wainwright | Neutral |
| 2017-12-08 | Eingeleitet | Citigroup | Buy |
| 2017-12-05 | Eingeleitet | JP Morgan | Overweight |
| 2017-11-13 | Eingeleitet | CL King | Buy |
| 2017-10-02 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | Eingeleitet | William Blair | Outperform |
| 2017-02-13 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Repligen Corp Aktie (RGEN) Neueste Nachrichten
Repligen to acquire BioLife for $11.25 cash plus 0.1442 shares per BioLife share; HSR waiting period expired - TradingView
[425] REPLIGEN CORP Business Combination Communication | RGEN SEC FilingForm 425 - Stock Titan
Repligen (RGEN) CEO trades stock in preset plan - Stock Titan
REPLIGEN CORP SEC Filing (Sep 8, 2026) - Stock Titan
Repligen Stock Price Forecast. Should You Buy RGEN? - StockInvest.us
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup - ChartMill
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - valueresearchonline.com
Repligen (RGEN) holder lines up new sale after $976K trade - Stock Titan
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share - Stock Titan
Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound - Yahoo Finance
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
Repligen (NASDAQ: RGEN) awards 2,466 stock units to its chief accounting officer - Stock Titan
A Look at Repligen Corp (RGEN) After 6.1% Decline -- GF Value $1 - GuruFocus
Acutus Medical Inc (AFIB) Peer Comparison – Compare with Others - Value Research
Repligen Corporation (RGEN) Stock Price, Chart, News & Analysis - securities.io
Repligen Corp (RGEN) Shares Fall 3.2% -- What GF Score of 87 Tel - GuruFocus
Repligen Corporation (RGEN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Repligen’s CEO and CFO join Wells Fargo conference Sept. 9 - Stock Titan
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen (NASDAQ: RGEN) CEO trades shares at $180 under 10b5-1 plan - Stock Titan
LVIP Baron Growth Opportunities Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen rises as investors continue to digest raised 2026 guidance and the BioLife deal - Quiver Quantitative
Repligen (NASDAQ: RGEN) plan covers 5,426-share sale after option exercise - Stock Titan
Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com - Investing.com South Africa
Repligen Corporation stock hits 52-week high at 176.52 USD - Investing.com
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks - Yahoo Finance
Oppenheimer Asset Management Inc. Purchases New Position in Repligen Corporation $RGEN - MarketBeat
Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A - Stock Titan
Repligen Corporation (RGEN) Stock Forecasts - Yahoo! Finance Canada
Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN - MarketBeat
Assenagon Asset Management S.A. Buys New Shares in Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026 - Yahoo Finance
Repligen Corp (RGEN) Stock News Today - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
The Manufacturers Life Insurance Company Decreases Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late to Buy Repligen Corp (RGEN) After 5.8% Rally? GF Value Says Undervalued - GuruFocus
Moody National Bank Trust Division Makes New Investment in Repligen Corporation $RGEN - MarketBeat
California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN - MarketBeat
Repligen Submits Form 425 Detailing Proposed Acquisition of BioLife Solutions - Kalkine Media
Repligen Corp (RGEN) Stock Up 4.3% and Still Undervalued -- GF S - GuruFocus
Repligen Earnings: Excellent Profit Margins, China Recovery Underway - Morningstar
Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP - MarketBeat
Vanguard Capital Management reports 5% Repligen (RGEN) stake in Schedule 13G - Stock Titan
Repligen Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup - ChartMill
Repligen Corp 2026 Q2 10-Q SEC Filing: Financial Statements, Risk Factors, and Company Information - Minichart
Finanzdaten der Repligen Corp-Aktie (RGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):